Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ADC Therapeutics SA Common Shares
(NY:
ADCT
)
1.650
+0.110 (+7.14%)
Delayed Quote
Updated: 10:36 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ADC Therapeutics SA Common Shares
< Previous
1
2
3
4
5
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
June 23, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT
June 16, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
June 09, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
January 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
December 30, 2025
From
Pomerantz LLP
Via
GlobeNewswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough
June 26, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END
Via
FinancialNewsMedia
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
October 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
September 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Present at Upcoming Investor Conferences
September 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
August 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
July 30, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
July 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
June 27, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
June 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 15, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
May 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
May 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
April 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
April 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 13, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
